Kalohexis, Inc.

Pre-IPO issuer

ipo filed CONFIDENTIAL-S1

Kalohexis, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: CONFIDENTIAL-S1 on 2026-07-07.

Filing Timeline

Synthetic IPOGrid ID

CONFIDENTIAL-S1 filed

Confidential registration lead

Kalohexis said on July 7, 2026 that it confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering of common stock. Fierce Biotech independently reported the same-day confidential IPO filing and noted the company is an Endevica Bio spinout launched on March 19, 2026. BioSpace reported on July 8 that the registration statement remained confidential and that share count, proceeds and timing were still undisclosed. The March spinout announcement described Kalohexis as a clinical-stage metabolic-disease biotech with lead programs 710GO in obesity and mifomelatide in cancer cachexia. Fierce Biotech said Kalohexis is led by CEO Russell Potterfield and cited prior company positioning from Chief Medical and Scientific Officer Daniel Marks around differentiation from GLP-1 therapies.

Common stock in a proposed initial public offering · Use of proceeds Not disclosed while the draft registration statement remains confidential; sector coverage tied the IPO to funding Kalohexis' obesity and cachexia pipeline.

Kalohexis became a net-new confidential filing lead on July 7, 2026 when the company announced it had submitted a confidential draft S-1 for a proposed U.S. IPO. Independent biotech trade coverage the same day and next day confirmed the filing and framed it as a post-spinout financing step for the March 2026 Endevica carve-out.

2026-07-07 · CONFIDENTIAL-8E53185BBEAFB6224977

Comparable Deals

Not enough completed IPOs with similar characteristics to show comparables yet.

Recent News

Obesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoff

BioSpace · 2026-07-08T00:00:00.000Z

Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s

Fierce Biotech · 2026-07-07T14:21:00.000Z

Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

PR Newswire · 2026-07-07T12:00:00.000Z

Endevica Announces Spinout of Kalohexis to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases

PR Newswire · 2026-03-19T12:00:00.000Z